The Association of District Chemists and Drugs in Bangalore (BDCDA) wrote to the Indian CEO (DCGI), who demanded immediate regulatory measures against two health technological startups dealing with alleged unauthorized manipulation and repetition of legal medicine.
In a letter of 30 July, BDCDA claimed that such events were contrary to the 1940 drug and cosmetics law and the 1945 rules.
Pointing out that the organization of chemists and pharmacies (AiCD) of all India (AiCD) has already taken the question of one such startup at national level, BDCDA said that manipulation of legal packaging, unlawful drug translations and ignoring major stability and marking standards by two medical companies threaten public health.
A specific violation
Emphasizing specific violations under the 1940 drug and cosmetics Act and rules of 1945, President BDCD B. Thirunavukkaras told the Hinds that such actions were deliberate destruction or removal of statutory labels, batch numbers, the date of getting on and They are in the mount and are of regular numbers, and thus continue to be in the mount. act.
The threat to stability, efficiency and therapeutic efficacy of medicinal products by exposing them to contamination and temperature changes through misunderstanding, storage and changing procedures that represent an annex P1.
Violation of GMP and GSP
“Carrying Out repacking in unlicensed, non-compliant, and unControlled Environments Grossly Violates the Prince of Good Manufacturing Practices (GMP) and Good Storage Practics (GSP) ‘Tech-enable Innovations’, Or ‘Patient-Friendly Services’ Mislead Consumers and Erode the Creditity of India’s Ethical Pharmacy community, “he said.
In addition to all these violations, the sale of medicinal products continues through online platforms and lacks any legal permits or structured regulatory mechanism, added Mr. Thirunavukkaras.
Published – 1 August 2025 9:09
